QuadMedicine Inc

QuadMedicine Inc has a liquidity position that appears robust, with a current ratio of 2.87, indicating that the company has more than twice as many current assets as current liabilities. The company's cash and equivalents amount to 26,506,644,330 KRW, which is a significant portion of its total assets of 51,179,024,990 KRW. However, the company's operating cash flow is negative at -4,547,392,510 KRW, and its free cash flow is also negative at -6,050,213,170 KRW, suggesting that the company is not generating positive cash from operations. Profitability metrics for QuadMedicine Inc are negative, with a return on equity of -0.225 and a return on assets of -0.1354. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit. The company's operating income is negative at -6,383,678,520 KRW, and its net income is also negative at -6,931,050,750 KRW, reflecting a challenging financial performance. The company's revenue is primarily concentrated in its pharmaceutical segment, which is engaged in the development and research of synthetic drugs and vaccine products through the CDMO model. The other segment, which provides research services, contributes to the company's revenue but is not as significant as the pharmaceutical segment. The company's geographic exposure is primarily within Korea, as it is a Korea-based company. The growth trajectory of QuadMedicine Inc is currently negative, with a net income of -6,931,050,750 KRW and an operating income of -6,383,678,520 KRW. The company's revenue for the latest period is 10,698,152,630 KRW, but there is no indication of a positive growth trend. The company's capital expenditure is negative at -2,415,098,420 KRW, suggesting that the company is not investing in new projects or expanding its operations. Risk factors for QuadMedicine Inc include a low liquidity position, as indicated by the negative operating and free cash flows. The company's debt to equity ratio is 0.24, which is relatively low, but the company's total liabilities of 20,379,824,400 KRW are a concern given the negative net income. The company's dilution potential is low, and there are no immediate filing-based liquidity or dilution flags detected. Recent events for QuadMedicine Inc include the latest financial snapshot, which shows a negative operating income and net income. The company's financial performance is a concern, and there are no indications of recent positive developments or events that would suggest an improvement in the company's financial position.